- The company has initiated cell line development for its lead BiTAC(R) T-cell engager program, selecting ATUM to support manufacturing development as the candidate advances toward IND/CTA-enabling studies.
- ATUM will apply its Leap-In Transposase(R) technology to generate stable clonal cell lines for VERAXA’s lead therapeutic candidate.
- The collaboration represents an important development milestone, supporting manufacturing, analytical development and nonclinical studies required before clinical testing.
- VERAXA’s BiTAC(R) platform is designed to improve the selectivity of T-cell engagers, potentially reducing toxicity associated with conventional approaches.
- The company recently expanded its research facilities in Heidelberg, Germany, increasing laboratory capacity as multiple oncology programs move toward clinical development.
VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has begun cell line development for its lead BiTAC(R) T-cell engager (“BiTAC(R)-TCE”) program, marking another step in preparing the company’s most advanced oncology candidate for future clinical development.
The company announced that it has selected ATUM, a U.S.-based contract research organization specializing in bioengineering and cell line development, to generate stable clonal cell lines using its proprietary Leap-In Transposase(R) technology. According to VERAXA, the collaboration is intended to support the program as it advances toward investigational new drug (“IND”) and clinical trial application (“CTA”)-enabling activities (https://ibn.fm/FNr1C).
Although often less visible than clinical trial announcements, cell line development represents an important stage in biologic drug development. Before antibody therapies can enter human studies, developers must establish manufacturing systems capable of consistently producing sufficient quantities of highly uniform therapeutic material. Stable clonal cell lines serve as the foundation for that manufacturing process, supporting process development, analytical testing, formulation work and production of material required for nonclinical studies.
VERAXA said the resulting cell lines will be used throughout its chemistry, manufacturing and controls (“CMC”) development program as preparations continue for regulatory submissions.
The company selected ATUM because its Leap-In Transposase(R) platform is designed to support efficient production of complex multi-chain biologic molecules such as VERAXA’s BiTAC(R) T-cell engagers. According to the company, ATUM’s technology has previously supported stable cell line generation for more than 50 investigational new drug submissions, providing an established manufacturing approach for advanced antibody formats.
The announcement follows encouraging preclinical data that VERAXA presented earlier this year at the American Association for Cancer Research (“AACR”) Annual Meeting. Those studies evaluated the company’s lead BiTAC(R)-TCE candidate in laboratory and animal models, where the therapy demonstrated selective activity against cancer cells expressing both intended target antigens while sparing cells carrying only one target. The results reflected the underlying design of VERAXA’s proprietary BiTAC(R) platform.
Traditional T-cell engagers generally function by simultaneously binding a tumor-associated protein and the CD3 receptor on T-cells, directing the immune system to attack cancer cells. While the approach has demonstrated clinical benefit in certain cancers, many conventional T-cell engagers face development challenges because the targeted proteins may also be present on healthy tissue, increasing the risk of unintended immune activation and treatment-related toxicity.
VERAXA’s BiTAC(R) strategy seeks to address that limitation through a different molecular design. Instead of delivering one fully active molecule, the technology divides the therapeutic into two complementary precursor molecules. Each precursor independently recognizes a different tumor-associated target but remains incapable of activating T-cells on its own.
Only when both precursors bind simultaneously to two distinct targets on the same cancer cell is the CD3-binding function reconstructed, activating the immune response. This “AND-gated” mechanism is intended to concentrate T-cell activity on cells displaying both target markers while reducing effects on healthy tissues expressing only one antigen.
The company believes this conditional activation approach could broaden the therapeutic window by maintaining anti-cancer activity while reducing off-target toxicity. That hypothesis will require further validation through future preclinical and clinical studies.
VERAXA has also continued investing in its broader research infrastructure. In June, the company announced a more than 60% expansion of laboratory space at its research and development facility in Heidelberg, Germany (https://ibn.fm/O6eTH). The additional capacity is intended to accommodate planned research staff growth, new laboratory equipment and expanded development activities as multiple proprietary and partnered programs move toward early clinical development.
The Heidelberg location also places VERAXA within one of Europe’s established biomedical research clusters, providing proximity to academic institutions and oncology research organizations.
The company continues to build a diversified oncology pipeline that extends beyond its BiTAC(R) platform. Alongside BiTAC(R) T-cell engagers, VERAXA is developing bispecific antibody-drug conjugates (“ADCs”), additional engineered antibody formats and other oncology candidates derived from technologies originally developed through scientific discoveries at the European Molecular Biology Laboratory (“EMBL”).
For more information, visit the company’s website at www.Veraxa.com.
NOTE TO INVESTORS: The latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA
About MissionIR
MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.
MIR is where breaking news, insightful content and actionable information converge.
For more information, please visit www.MissionIR.com
Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer
MissionIR
Austin, Texas
www.MissionIR.com
512.354.7000 Office
Editor@MissionIR.com
MissionIR is powered by IBN